Salvage therapy in Hodgkin's lymphoma

Oncologist

Volumn 12, Issue 2, 2007, Pages 156-167

  Byrne, Brian J ^a   Gockerman, Jon P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autologous transplant; Hodgkin's disease; Radiation therapy; Salvage therapy

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOGUAZONE; MONOCLONAL ANTIBODY; NAVELBINE; PREDNISONE; PROCARBAZINE; RITUXIMAB; STEROID; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBODY LABELING; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RELAPSE; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; RECURRENCE RISK; SALVAGE THERAPY; TREATMENT FAILURE;

COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY;

EID: 33847047457     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-2-156     Document Type: Article

References (69)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Harris NL. Hodgkin's disease: Classification and differential diagnosis. Mod Pathol 1999;12:159-175.
3. Ekstrand BC, Horning SJ. Hodgkin's disease. Blood Rev 2002;16:111-117.
4. Engels EA, Goedert JJ. Human immunodeficiency virus/acquired immunodeficiency syndrome and cancer: Past, present, and future. J Natl Cancer Inst 2005;97:407-409.
5. Longo DL, Young RC, Wesley M et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986;4:1295-1306.
6. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1484.
7. Meyer RM, Gospodarowicz MK, Connors JM et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634-4642.
8. Kuppers R, Yahalom J, Josting A. Advances in biology, diagnostics, and treatment of Hodgkin's disease. Biol Blood Marrow Transplant 2006;12(suppl 1):66-76.
9. Duggan DB, Petroni GR, Johnson JL et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 2003;21:607-614.
10. Horning SJ, Williams J, Bartlett NL et al. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 2000;18:972-980.
11. Federico M, Levis A, Luminari S et al. ABVD vs. STANFORD V (SV) vs. MOPP-EBV-CAD (MEC) in advanced Hodgkin's lymphoma. Final results of the IIL HD9601 randomized trial. J Clin Oncol 2004;22(suppl):6507.
12. Johnson P, Hoskin P, Horwich A et al. Stanford V (SV) regimen versus ABVD for the treatment of advanced Hodgkin lymphoma (HL): Results of a UK NCRI/LTO randomised phase II trial. Proc Am Soc Hematol 2004;104:311.
13. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-2395.
14. Diehl V, Behringer K. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma? Cancer Invest 2006;24:461-465.
15. Bonadonna G, Santoro A. ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 1982;9:21-35.
16. Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970;73:881-895.
17. Gallamini A, Rigacci L, Merli F et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006;91:475-481.
18. Longo DL, Duffey PL, Young RC et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 1992;10:210-218.
19. Bonfante V, Santoro A, Viviani S et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997;15:528-534.
20. Lohri A, Barnett M, Fairey RN et al. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: Identification of risk factors from the British Columbia experience 1970 to 1988. Blood 1991;77:2292-2298.
21. Armitage JO, Bierman PJ, Vose JM et al. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med 1991;91:605-611.
22. Carella AM, Congiu AM, Gaozza E et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: An Italian study group report. J Clin Oncol 1988;6:1411-1416.
23. Jagannath S, Dicke KA, Armitage JO et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 1986;104:163-168.
24. Phillips GL, Wolff SN, Herzig RH et al. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 1989;73:2086-2092.
25. Moskowitz C. An update on the management of relapsed and primary refractory Hodgkin's disease. Semin Oncol 2004;31(suppl):54-59.
26. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993;341:1051-1054.
27. Schmitz N, Pfistner B, SextroMet al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:A randomised trial. Lancet 2002;359:2065-2071.
28. Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model. Blood 2001;97:616-623.
29. Horning SJ, Chao NJ, Negrin RS et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 1997;89:801-813.
30. Holland DW, Engelhardt BG, Goodman SA et al. High dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin's Lymphoma. J Clin Oncol 2006;24(suppl):7552.
31. Moskowitz CH, Kewalramani T, Nimer SD et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004;124:645-652.
32. Sirohi B, Cunningham D, Norman RA et al. Long-term outcome of high-dose chemotherapy and autologous stem cell transplantation in relapsed/ refractory Hodgkin's disease: A cohort of 199 pts from Royal Mardsen Hospital. J Clin Oncol 2006;24(suppl):7622.
33. Aparicio J, Segura A, Garcera S et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 1999;10:593-595.
34. Aviles A, Neri N, Garcia EL et al. Treatment of refractory Hodgkin's disease with modified Stanford V program. Med Oncol 2001;18:261-267.
35. Baetz T, Belch A, Couban S et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease:Aphase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003;14:1762-1767.
36. Bonfante V, Viviani S, Devizzi L et al. High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease. Eur J Haematol 2001;64(suppl):51-55.
37. Colwill R, Crump M, Couture F et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995;13:396-402.
38. Enblad G, Hagberg H, Gustavsson A et al. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: A prospective study. Eur J Haematol 1998;60:166-171.
39. Ferme C, Bastion Y, Lepage E et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 1995;6:543-549.
40. Fernandez-Jimenez MC, Canales MA, Ojeda E et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation. Haematologica 1999;84:1007-1011.
41. Jackson GH, Angus B, Carey PJ et al. High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: A report on toxicity and efficacy. Leuk Lymphoma 2000;37:561-570.
42. Josting A, Rudolph C, Reiser M et al. Time-intensified dexamethasone/ cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002;13:1628-1635.
43. Oyan B, Koc Y, Ozdemir E et al. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma:Asalvage regimen with high response rates before autologous stem cell transplantation. Biol Blood Marrow Transplant 2005;11:688-697.
44. Proctor SJ, Taylor PR, Angus B et al. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: A report on toxicity and efficacy. Eur J Haematol 2001;64(suppl):28-32.
45. Ribrag V, Nasr F, Bouhris JH et al. VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease. Bone Marrow Transplant 1998;21:969-974.
46. Rodriguez J, Rodriguez MA, Fayad L et al. ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 1999;93:3632-3636.
47. Szanto I, Fleischmann T, Eckhardt S. Treatment of resistant Hodgkin's disease with CCNU, etoposide and prednimustine (CEP). Oncology 1991;48:456-458.
48. Walewski J, Krzyzanowska JB, Kraszewska E et al. CN3OP: An active regimen in patients with relapsed/refractory Hodgkin's lymphoma. Med Oncol 2000;17:195-202.
49. Wiernik PH, Dutcher JP, Einzig AI et al. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): A highly active regimen for advanced and poor-prognosis Hodgkin's disease. Cancer J Sci Am 1998;4:254-260.
50. Santoro A, Bredenfeld H, Devizzi L et al. Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study. J Clin Oncol 2000;18:2615-2619.
51. Venkatesh H, Di Bella N, Flynn TP et al. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma 2004;5:110-115.
52. Zinzani PL, Bendandi M, Stefoni V et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 2000;85:926-929.
53. Aurer I, Radman I, Nemet D et al. Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease. Onkologie 2005;28:567-571.
54. Carter SK, Livingston RB. Single-agent therapy for Hodgkin's disease. Arch Intern Med 1973;131:377-387.
55. Little R, Wittes RE, Longo DL et al. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol 1998;16:584-588.
56. Devizzi L, Santoro A, Bonfante V et al. Vinorelbine: An active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol 1994;5:817-820.
57. Rule S, Tighe M, Davies S et al. Vinorelbine in the treatment of lymphoma. Hematol Oncol 1998;16:101-105.
58. Leigh BR, Fox KA, Mack CF et al. Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 1993;27:855-862.
59. Campbell B, Wirth A, Milner A et al. Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure. Int J Radiat Oncol Biol Phys 2005;63:1538-1545.
60. Josting A, Nogova L, Franklin J et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005;23:1522-1529.
61. Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996;14:572-578.
62. Milpied N, Fielding AK, Pearce RM et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996;14:1291-1296.
63. Akpek G, Ambinder RF, Piantadosi S et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001;19:4314-4321.
64. Anderlini P, Saliba R, Acholonu S et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: Low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005;35:943-951.
65. Peggs KS, Hunter A, Chopra R et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005;365:1934-1941.
66. Wahl AF, Klussman K, Thompson JD et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002;62:3736-3742.
67. Leonard JP, Rosenblatt JD, Bartlett NL et al. Phase II study of SGN-30 (anti-CD 30n monoclonal antibody) in patients with refractory or recurrent Hodgkin's disease. Blood 2004;104:2635.
68. Schnell R, Dietlein M, Staak JO et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 2005;23:4669-4678.
69. Younes A, Romaguera J, Hagemeister F et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98:310-314.